Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 124 entries
Sorted by: Best Match Show Resources per page
Introduction to sample size determination and power analysis for clinical trials.

Controlled clinical trials

Lachin JM.
PMID: 7273794
Control Clin Trials. 1981 Jun;2(2):93-113. doi: 10.1016/0197-2456(81)90001-5.

The importance of sample size evaluation in clinical trials is reviewed and a general method is presented from which specific equations are derived for sample size determination or the analysis of power for a wide variety os statistical procedures....

Cite
Lachin JM. Introduction to sample size determination and power analysis for clinical trials. Control Clin Trials. 1981;2(2):93-113doi: 10.1016/0197-2456(81)90001-5.
Lachin, J. M. (1981). Introduction to sample size determination and power analysis for clinical trials. Controlled clinical trials, 2(2), 93-113. https://doi.org/10.1016/0197-2456(81)90001-5
Lachin, J M. "Introduction to sample size determination and power analysis for clinical trials." Controlled clinical trials vol. 2,2 (1981): 93-113. doi: https://doi.org/10.1016/0197-2456(81)90001-5
Lachin JM. Introduction to sample size determination and power analysis for clinical trials. Control Clin Trials. 1981 Jun;2(2):93-113. doi: 10.1016/0197-2456(81)90001-5. PMID: 7273794.
Copy Download .nbib Format: NLM
Utility of using electrocardiogram measures of heart rate variability as a measure of cardiovascular autonomic neuropathy in type 1 diabetes patients.

Journal of diabetes investigation

Pop-Busui R, Backlund JC, Bebu I, Braffett BH, Lorenzi G, White NH, Lachin JM, Soliman EZ.
PMID: 34309223
J Diabetes Investig. 2022 Jan;13(1):125-133. doi: 10.1111/jdi.13635. Epub 2021 Aug 14.

AIMS/INTRODUCTION: Cardiovascular autonomic neuropathy (CAN) is a predictor of cardiovascular disease and mortality. Cardiovascular reflex tests (CARTs) are the gold standard for the diagnosis of CAN, but might not be feasible in large research cohorts or in clinical care....

Cite
Pop-Busui R, Backlund JC, Bebu I, et al. Utility of using electrocardiogram measures of heart rate variability as a measure of cardiovascular autonomic neuropathy in type 1 diabetes patients. J Diabetes Investig. 2021;13(1):125-133doi: 10.1111/jdi.13635.
Pop-Busui, R., Backlund, J. C., Bebu, I., Braffett, B. H., Lorenzi, G., White, N. H., Lachin, J. M., Soliman, E. Z. (2022). Utility of using electrocardiogram measures of heart rate variability as a measure of cardiovascular autonomic neuropathy in type 1 diabetes patients. Journal of diabetes investigation, 13(1), 125-133. https://doi.org/10.1111/jdi.13635
Pop-Busui, Rodica, et al. "Utility of using electrocardiogram measures of heart rate variability as a measure of cardiovascular autonomic neuropathy in type 1 diabetes patients." Journal of diabetes investigation vol. 13,1 (2022): 125-133. doi: https://doi.org/10.1111/jdi.13635
Pop-Busui R, Backlund JC, Bebu I, Braffett BH, Lorenzi G, White NH, Lachin JM, Soliman EZ. Utility of using electrocardiogram measures of heart rate variability as a measure of cardiovascular autonomic neuropathy in type 1 diabetes patients. J Diabetes Investig. 2022 Jan;13(1):125-133. doi: 10.1111/jdi.13635. Epub 2021 Aug 14. PMID: 34309223.
Copy Download .nbib Format: NLM
Hydroxychloroquine and azithromycin used alone or combined are not effective against SARS-CoV-2 ex vivo and in a hamster model.

Antiviral research

Cochin M, Touret F, Driouich JS, Moureau G, Petit PR, Laprie C, Solas C, de Lamballerie X, Nougairède A.
PMID: 34838583
Antiviral Res. 2021 Nov 24;197:105212. doi: 10.1016/j.antiviral.2021.105212. Epub 2021 Nov 24.

Drug repositioning has been used extensively since the beginning of the COVID-19 pandemic in an attempt to identify antiviral molecules for use in human therapeutics. Hydroxychloroquine and azithromycin have shown inhibitory activity against SARS-CoV-2 replication in different cell lines....

Cite
Cochin M, Touret F, Driouich JS, et al. Hydroxychloroquine and azithromycin used alone or combined are not effective against SARS-CoV-2 ex vivo and in a hamster model. Antiviral Res. 2021;197:105212doi: 10.1016/j.antiviral.2021.105212.
Cochin, M., Touret, F., Driouich, J. S., Moureau, G., Petit, P. R., Laprie, C., Solas, C., de Lamballerie, X., & Nougairède, A. (2021). Hydroxychloroquine and azithromycin used alone or combined are not effective against SARS-CoV-2 ex vivo and in a hamster model. Antiviral research, 197105212. https://doi.org/10.1016/j.antiviral.2021.105212
Cochin, Maxime, et al. "Hydroxychloroquine and azithromycin used alone or combined are not effective against SARS-CoV-2 ex vivo and in a hamster model." Antiviral research vol. 197 (2021): 105212. doi: https://doi.org/10.1016/j.antiviral.2021.105212
Cochin M, Touret F, Driouich JS, Moureau G, Petit PR, Laprie C, Solas C, de Lamballerie X, Nougairède A. Hydroxychloroquine and azithromycin used alone or combined are not effective against SARS-CoV-2 ex vivo and in a hamster model. Antiviral Res. 2021 Nov 24;197:105212. doi: 10.1016/j.antiviral.2021.105212. Epub 2021 Nov 24. PMID: 34838583; PMCID: PMC8611861.
Copy Download .nbib Format: NLM
Arabidopsis Growth-Promotion and Root Architecture Responses to the Beneficial Rhizobacterium .

Plants (Basel, Switzerland)

Kechid M, Desbrosses G, Gamet L, Castaings L, Varoquaux F, Djekoun A, Touraine B.
PMID: 35009131
Plants (Basel). 2022 Jan 04;11(1). doi: 10.3390/plants11010128.

No abstract available.

Cite
Kechid M, Desbrosses G, Gamet L, et al. Arabidopsis Growth-Promotion and Root Architecture Responses to the Beneficial Rhizobacterium . Plants (Basel). 2022;11(1)doi: 10.3390/plants11010128.
Kechid, M., Desbrosses, G., Gamet, L., Castaings, L., Varoquaux, F., Djekoun, A., & Touraine, B. (2022). Arabidopsis Growth-Promotion and Root Architecture Responses to the Beneficial Rhizobacterium . Plants (Basel, Switzerland), 11(1), . https://doi.org/10.3390/plants11010128
Kechid, Maya, et al. "Arabidopsis Growth-Promotion and Root Architecture Responses to the Beneficial Rhizobacterium ." Plants (Basel, Switzerland) vol. 11,1 (2022). doi: https://doi.org/10.3390/plants11010128
Kechid M, Desbrosses G, Gamet L, Castaings L, Varoquaux F, Djekoun A, Touraine B. Arabidopsis Growth-Promotion and Root Architecture Responses to the Beneficial Rhizobacterium . Plants (Basel). 2022 Jan 04;11(1). doi: 10.3390/plants11010128. PMID: 35009131.
Copy Download .nbib Format: NLM
Hydroxychloroquine and azithromycin used alone or combined are not effective against SARS-CoV-2 ex vivo and in a hamster model.

Antiviral research

Cochin M, Touret F, Driouich JS, Moureau G, Petit PR, Laprie C, Solas C, de Lamballerie X, Nougairède A.
PMID: 34838583
Antiviral Res. 2021 Nov 24;197:105212. doi: 10.1016/j.antiviral.2021.105212. Epub 2021 Nov 24.

Drug repositioning has been used extensively since the beginning of the COVID-19 pandemic in an attempt to identify antiviral molecules for use in human therapeutics. Hydroxychloroquine and azithromycin have shown inhibitory activity against SARS-CoV-2 replication in different cell lines....

Cite
Cochin M, Touret F, Driouich JS, et al. Hydroxychloroquine and azithromycin used alone or combined are not effective against SARS-CoV-2 ex vivo and in a hamster model. Antiviral Res. 2021;197:105212doi: 10.1016/j.antiviral.2021.105212.
Cochin, M., Touret, F., Driouich, J. S., Moureau, G., Petit, P. R., Laprie, C., Solas, C., de Lamballerie, X., & Nougairède, A. (2021). Hydroxychloroquine and azithromycin used alone or combined are not effective against SARS-CoV-2 ex vivo and in a hamster model. Antiviral research, 197105212. https://doi.org/10.1016/j.antiviral.2021.105212
Cochin, Maxime, et al. "Hydroxychloroquine and azithromycin used alone or combined are not effective against SARS-CoV-2 ex vivo and in a hamster model." Antiviral research vol. 197 (2021): 105212. doi: https://doi.org/10.1016/j.antiviral.2021.105212
Cochin M, Touret F, Driouich JS, Moureau G, Petit PR, Laprie C, Solas C, de Lamballerie X, Nougairède A. Hydroxychloroquine and azithromycin used alone or combined are not effective against SARS-CoV-2 ex vivo and in a hamster model. Antiviral Res. 2021 Nov 24;197:105212. doi: 10.1016/j.antiviral.2021.105212. Epub 2021 Nov 24. PMID: 34838583; PMCID: PMC8611861.
Copy Download .nbib Format: NLM
Shape decomposition algorithms for laser capture microdissection.

Algorithms for molecular biology : AMB

Selbach L, Kowalski T, Gerwert K, Buchin M, Mosig A.
PMID: 34238311
Algorithms Mol Biol. 2021 Jul 08;16(1):15. doi: 10.1186/s13015-021-00193-6.

BACKGROUND: In the context of biomarker discovery and molecular characterization of diseases, laser capture microdissection is a highly effective approach to extract disease-specific regions from complex, heterogeneous tissue samples. For the extraction to be successful, these regions have to...

Cite
Selbach L, Kowalski T, Gerwert K, et al. Shape decomposition algorithms for laser capture microdissection. Algorithms Mol Biol. 2021;16(1):15doi: 10.1186/s13015-021-00193-6.
Selbach, L., Kowalski, T., Gerwert, K., Buchin, M., & Mosig, A. (2021). Shape decomposition algorithms for laser capture microdissection. Algorithms for molecular biology : AMB, 16(1), 15. https://doi.org/10.1186/s13015-021-00193-6
Selbach, Leonie, et al. "Shape decomposition algorithms for laser capture microdissection." Algorithms for molecular biology : AMB vol. 16,1 (2021): 15. doi: https://doi.org/10.1186/s13015-021-00193-6
Selbach L, Kowalski T, Gerwert K, Buchin M, Mosig A. Shape decomposition algorithms for laser capture microdissection. Algorithms Mol Biol. 2021 Jul 08;16(1):15. doi: 10.1186/s13015-021-00193-6. PMID: 34238311; PMCID: PMC8265035.
Copy Download .nbib Format: NLM
Early-Onset Leptomeningeal Manifestation of G47R Hereditary Transthyretin Amyloidosis.

Neurology. Clinical practice

Cechin L, Gasmelseed J, Bashford J, Rowczenio D, Reilly MM, Gillmore JD, Coutinho E.
PMID: 34840900
Neurol Clin Pract. 2021 Oct;11(5):e757-e759. doi: 10.1212/CPJ.0000000000001054.

No abstract available.

Cite
Cechin L, Gasmelseed J, Bashford J, et al. Early-Onset Leptomeningeal Manifestation of G47R Hereditary Transthyretin Amyloidosis. Neurol Clin Pract. 2021;11(5):e757-e759doi: 10.1212/CPJ.0000000000001054.
Cechin, L., Gasmelseed, J., Bashford, J., Rowczenio, D., Reilly, M. M., Gillmore, J. D., & Coutinho, E. (2021). Early-Onset Leptomeningeal Manifestation of G47R Hereditary Transthyretin Amyloidosis. Neurology. Clinical practice, 11(5), e757-e759. https://doi.org/10.1212/CPJ.0000000000001054
Cechin, Laura, et al. "Early-Onset Leptomeningeal Manifestation of G47R Hereditary Transthyretin Amyloidosis." Neurology. Clinical practice vol. 11,5 (2021): e757-e759. doi: https://doi.org/10.1212/CPJ.0000000000001054
Cechin L, Gasmelseed J, Bashford J, Rowczenio D, Reilly MM, Gillmore JD, Coutinho E. Early-Onset Leptomeningeal Manifestation of G47R Hereditary Transthyretin Amyloidosis. Neurol Clin Pract. 2021 Oct;11(5):e757-e759. doi: 10.1212/CPJ.0000000000001054. PMID: 34840900; PMCID: PMC8610556.
Copy Download .nbib Format: NLM
Understanding Metabolic Memory: The Prolonged Influence of Glycemia During the Diabetes Control and Complications Trial (DCCT) on Future Risks of Complications During the Study of the Epidemiology of Diabetes Interventions and Complications (EDIC).

Diabetes care

Lachin JM, Nathan DM.
PMID: 34548284
Diabetes Care. 2021 Sep 21; doi: 10.2337/dc20-3097. Epub 2021 Sep 21.

The Diabetes Control and Complications Trial (DCCT, 1983-1993) showed that intensive therapy (mean HbA

Cite
Lachin JM, Nathan DM. Understanding Metabolic Memory: The Prolonged Influence of Glycemia During the Diabetes Control and Complications Trial (DCCT) on Future Risks of Complications During the Study of the Epidemiology of Diabetes Interventions and Complications (EDIC). Diabetes Care. 2021;doi: 10.2337/dc20-3097.
Lachin, J. M., Nathan, D. M. (2021). Understanding Metabolic Memory: The Prolonged Influence of Glycemia During the Diabetes Control and Complications Trial (DCCT) on Future Risks of Complications During the Study of the Epidemiology of Diabetes Interventions and Complications (EDIC). Diabetes care, . https://doi.org/10.2337/dc20-3097
Lachin, John M, et al. "Understanding Metabolic Memory: The Prolonged Influence of Glycemia During the Diabetes Control and Complications Trial (DCCT) on Future Risks of Complications During the Study of the Epidemiology of Diabetes Interventions and Complications (EDIC)." Diabetes care vol. (2021). doi: https://doi.org/10.2337/dc20-3097
Lachin JM, Nathan DM. Understanding Metabolic Memory: The Prolonged Influence of Glycemia During the Diabetes Control and Complications Trial (DCCT) on Future Risks of Complications During the Study of the Epidemiology of Diabetes Interventions and Complications (EDIC). Diabetes Care. 2021 Sep 21; doi: 10.2337/dc20-3097. Epub 2021 Sep 21. PMID: 34548284.
Copy Download .nbib Format: NLM
Welcome to the One Electron World.

Chimia

Lachia M, Kolleth-Krieger A.
PMID: 32264998
Chimia (Aarau). 2020 Feb 26;74(1):8.

No abstract available.

Cite
Lachia M, Kolleth-Krieger A. Welcome to the One Electron World. Chimia (Aarau). 2020;74(1):8
Lachia, M., & Kolleth-Krieger, A. (2020). Welcome to the One Electron World. Chimia, 74(1), 8.
Lachia, Mathilde, and Kolleth-Krieger, Amandine. "Welcome to the One Electron World." Chimia vol. 74,1 (2020): 8.
Lachia M, Kolleth-Krieger A. Welcome to the One Electron World. Chimia (Aarau). 2020 Feb 26;74(1):8. PMID: 32264998.
Copy Download .nbib Format: NLM
Serum-deprived differentiated neuroblastoma F-11 cells express functional dorsal root ganglion neuron properties.

PeerJ

Pastori V, D'Aloia A, Blasa S, Lecchi M.
PMID: 31687277
PeerJ. 2019 Oct 30;7:e7951. doi: 10.7717/peerj.7951. eCollection 2019.

The isolation and culture of dorsal root ganglion (DRG) neurons cause adaptive changes in the expression and regulation of ion channels, with consequences on neuronal excitability. Considering that not all neurons survive the isolation and that DRG neurons are...

Cite
Pastori V, D'Aloia A, Blasa S, et al. Serum-deprived differentiated neuroblastoma F-11 cells express functional dorsal root ganglion neuron properties. PeerJ. 2019;7:e7951doi: 10.7717/peerj.7951.
Pastori, V., D'Aloia, A., Blasa, S., & Lecchi, M. (2019). Serum-deprived differentiated neuroblastoma F-11 cells express functional dorsal root ganglion neuron properties. PeerJ, 7e7951. https://doi.org/10.7717/peerj.7951
Pastori, Valentina, et al. "Serum-deprived differentiated neuroblastoma F-11 cells express functional dorsal root ganglion neuron properties." PeerJ vol. 7 (2019): e7951. doi: https://doi.org/10.7717/peerj.7951
Pastori V, D'Aloia A, Blasa S, Lecchi M. Serum-deprived differentiated neuroblastoma F-11 cells express functional dorsal root ganglion neuron properties. PeerJ. 2019 Oct 30;7:e7951. doi: 10.7717/peerj.7951. eCollection 2019. PMID: 31687277; PMCID: PMC6825413.
Copy Download .nbib Format: NLM
Magnesium alginate versus proton pump inhibitors for the treatment of laryngopharyngeal reflux: a non-inferiority randomized controlled trial.

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery

Pizzorni N, Ambrogi F, Eplite A, Rama S, Robotti C, Lechien J, Schindler A.
PMID: 35032204
Eur Arch Otorhinolaryngol. 2022 Jan 15; doi: 10.1007/s00405-021-07219-0. Epub 2022 Jan 15.

PURPOSE: Proton pump inhibitors (PPIs) are commonly prescribed for laryngopharyngeal reflux (LPR), but their efficacy remains debated. Alginates is an option for the treatment of LPR with few adverse effects. The study aimed to investigate the non-inferiority of an...

Cite
Pizzorni N, Ambrogi F, Eplite A, et al. Magnesium alginate versus proton pump inhibitors for the treatment of laryngopharyngeal reflux: a non-inferiority randomized controlled trial. Eur Arch Otorhinolaryngol. 2022;doi: 10.1007/s00405-021-07219-0.
Pizzorni, N., Ambrogi, F., Eplite, A., Rama, S., Robotti, C., Lechien, J., & Schindler, A. (2022). Magnesium alginate versus proton pump inhibitors for the treatment of laryngopharyngeal reflux: a non-inferiority randomized controlled trial. European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, . https://doi.org/10.1007/s00405-021-07219-0
Pizzorni, Nicole, et al. "Magnesium alginate versus proton pump inhibitors for the treatment of laryngopharyngeal reflux: a non-inferiority randomized controlled trial." European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery vol. (2022). doi: https://doi.org/10.1007/s00405-021-07219-0
Pizzorni N, Ambrogi F, Eplite A, Rama S, Robotti C, Lechien J, Schindler A. Magnesium alginate versus proton pump inhibitors for the treatment of laryngopharyngeal reflux: a non-inferiority randomized controlled trial. Eur Arch Otorhinolaryngol. 2022 Jan 15; doi: 10.1007/s00405-021-07219-0. Epub 2022 Jan 15. PMID: 35032204.
Copy Download .nbib Format: NLM
Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trial.

ESC heart failure

Fitchett D, Inzucchi SE, Zinman B, Wanner C, Schumacher M, Schmoor C, Ohneberg K, Ofstad AP, Salsali A, George JT, Hantel S, Bluhmki E, Lachin JM, Zannad F.
PMID: 34605192
ESC Heart Fail. 2021 Oct 04; doi: 10.1002/ehf2.13615. Epub 2021 Oct 04.

AIMS: In the EMPA-REG OUTCOME trial, empagliflozin reduced risk of death from heart failure (HF) or hospitalization for heart failure (HHF) versus placebo in patients with type 2 diabetes mellitus (T2DM) and established cardiovascular (CV) disease. We evaluated post...

Cite
Fitchett D, Inzucchi SE, Zinman B, et al. Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trial. ESC Heart Fail. 2021;doi: 10.1002/ehf2.13615.
Fitchett, D., Inzucchi, S. E., Zinman, B., Wanner, C., Schumacher, M., Schmoor, C., Ohneberg, K., Ofstad, A. P., Salsali, A., George, J. T., Hantel, S., Bluhmki, E., Lachin, J. M., & Zannad, F. (2021). Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trial. ESC heart failure, . https://doi.org/10.1002/ehf2.13615
Fitchett, David, et al. "Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trial." ESC heart failure vol. (2021). doi: https://doi.org/10.1002/ehf2.13615
Fitchett D, Inzucchi SE, Zinman B, Wanner C, Schumacher M, Schmoor C, Ohneberg K, Ofstad AP, Salsali A, George JT, Hantel S, Bluhmki E, Lachin JM, Zannad F. Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trial. ESC Heart Fail. 2021 Oct 04; doi: 10.1002/ehf2.13615. Epub 2021 Oct 04. PMID: 34605192.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 124 entries